Haemonetics CORP Schedule 13G passive stakes

AQR Capital Management, LLC and AQR Capital Management Holdings, LLC have filed an amendment to their Schedule 13G, reporting beneficial ownership of Haemonetics Corp. common stock.

North Peak Capital Management and affiliated entities have filed an amendment to their Schedule 13G, reporting 0% beneficial ownership of Haemonetics Corp. common stock as of March 31, 2026.

Vanguard Capital Management has reported beneficial ownership of 5.26% of Haemonetics Corp. common stock as of March 31, 2026.

Vanguard Portfolio Management has reported beneficial ownership of 5.59% of Haemonetics Corp's common stock as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Haemonetics Corp following an internal realignment that disaggregated reporting responsibilities.

North Peak Capital Management, LLC and affiliated entities have reported a 5.1% beneficial ownership stake in Haemonetics Corporation, totaling 2,370,495 shares.

AQR Capital Management, LLC and its parent entity have reported a beneficial ownership of 6.76% in Haemonetics Corp, totaling 3,163,104 shares.

Wellington Management Group LLP and its affiliates reported a 4.6% beneficial ownership stake in Haemonetics Corporation as of June 30, 2025.

T. Rowe Price Investment Management, Inc. has filed an amended Schedule 13G, reporting a 4.4% beneficial ownership stake in Haemonetics Corp/Mass as of March 31, 2025.

Wellington Management Group LLP and its affiliates have filed an amended Schedule 13G, reporting a 5.4% beneficial ownership stake in Haemonetics Corporation as of March 31, 2025.

Capital Research Global Investors has filed an Amendment No. 4 to Schedule 13G, disclosing a continued 3.1% beneficial ownership stake in Haemonetics Corp. as of March 31, 2025.